IBX 9.76% 7.4¢ imagion biosystems limited

Nanoparticles SPIONS Exciting Future

  1. 316 Posts.
    lightbulb Created with Sketch. 192
    ***** Thought it was time to start a new thread ******

    Check out this recent paper funded by the Malaysian Ministry of Education, which is research into the use of Nanoparticles in the treatment of breast cancer.

    Nanoparticles Targeting Receptors on Breast Cancer for Efficient Delivery of Chemotherapeutics

    I am certainly not saying I understand the entire report but it does acknowledge that breast cancer is the most recurring malignancy and a foremost cause of cancer-related deaths in women, with the second highest incidence rate (11.6%) among all other cancers.

    This places the current Study of Imagion right on the global stage, all eyes will be watching as we already know.

    Check out the conclusion......very exciting!!!

    Conclusions and Future Prospective

    In summary, receptor-targeting of nanoparticles possesses a great perspective asan ideal drug delivery approach, forming the basis of an ever-expanding area of cancernanomedicine to circumvent the limitations of currently available chemotherapeutic agents.Vigorous research on tumor, tumor microenvironment, and metastasis resulted in discoveryof many promising molecular targets for tumor targeting and therapy. Meanwhile, tremen-dous progress on the design of diverse nanoparticles and understanding of their multiplebiological, pharmaceutical, and translational barriers introduced several smart nanocarriersand novel delivery approaches for improving the clinical impact of cancer nanomedicine.A variety of organic, inorganic, hybrid, and stimuli-responsive NPs were developed sofar to deliver multiple chemotherapeutics for the management of breast cancer. For activetargeting of the NPs, several ligands of different sizes and molecular entities were used totarget specific receptors which are overexpressed in breast cancer cells. Preclinical animalstudies demonstrated that the targeted NP-drug complexes enhanced cellular internaliza-tion and the therapeutic index of anticancer drugs and reduced unintended side effects andchemoresistance in breast cancer cells compared to free drugs. These exciting outcomeshold promise for clinical translation of therapeutic NPs. Further investigations are highlydesirable in the selection of an ideal receptor and in understanding the effects of proteincorona spontaneously formed on NPs in blood, the ligand–receptor interaction, the rateof internalization of drug-loaded NPs, and the drug-release mechanisms inside the targetcell. Employing combinatorial therapy, dual targeting strategies, and theranostic NPswould help to improve performance of the nanotherapeutics. Finally, precisely designedanimal models and the adoption of good laboratory practices (GLP) on the laboratoryscale may contribute to developing clinically translatable targeted nanotherapeutics for themanagement of breast cancer.
 
watchlist Created with Sketch. Add IBX (ASX) to my watchlist
(20min delay)
Last
7.4¢
Change
-0.008(9.76%)
Mkt cap ! $2.416M
Open High Low Value Volume
8.1¢ 8.1¢ 7.4¢ $999 13.18K

Buyers (Bids)

No. Vol. Price($)
2 33249 7.3¢
 

Sellers (Offers)

Price($) Vol. No.
8.2¢ 4896 2
View Market Depth
Last trade - 15.50pm 29/03/2024 (20 minute delay) ?
Last
7.3¢
  Change
-0.008 ( 1.35 %)
Open High Low Volume
7.3¢ 7.3¢ 7.3¢ 1812
Last updated 15.50pm 29/03/2024 ?
IBX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.